Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL⁺ cell to Imatinib and Nilotinib

References

• Nowell P, Hungerford D. A minute chromosome in chronic granulocytic leukemia. Science 1960; 132: 1497
   Web of Science ®Google Scholar
• de K A, van Kessel A G, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982; 300: 765–767
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker B J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640–2653
   PubMed Web of Science ®Google Scholar
• Deininger M W, Goldman J M, Lydon N, Melo J V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691–3698
   PubMed Web of Science ®Google Scholar
• Deininger M W, Vieira S, Mendiola R, et al. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 2000; 60: 2049–2055
   PubMed Web of Science ®Google Scholar
• Druker B J, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566
   PubMed Web of Science ®Google Scholar
• le C P, Mologni L, Cleris L, et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999; 91: 163–168
   PubMed Web of Science ®Google Scholar
• Druker B J, O'Brien S G, Cortes J, Radich J. Chronic myelogenous leukemia. Hematol Am Soc Hematol Educ Prog 2002; 111–135
   PubMedGoogle Scholar
• Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 4022–4028
   PubMed Web of Science ®Google Scholar
• Topaly J, Fruehauf S, Ho A D, Zeller W J. Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning. Br J Cancer 2002; 86: 1487–1493
   PubMed Web of Science ®Google Scholar
• Radujkovic A, Schad M, Topaly J, et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – inhibition of P-glycoprotein function by 17-AAG. Leukemia 2005; 19: 1198–1206
   PubMed Web of Science ®Google Scholar
• Radujkovic A, Topaly J, Fruehauf S, Zeller W J. Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors. Anticancer Res 2006; 26: 2169–2177
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters D K, Stoffregen E P, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500–4505
   PubMed Web of Science ®Google Scholar
• Shah N P, Tran C, Lee F Y, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399–401
   PubMed Web of Science ®Google Scholar
• Cortes J, Rousselot P, Kim D W, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207–3213
   PubMed Web of Science ®Google Scholar
• Bradstock K, Bianchi A, Makrynikola V, Filshie R, Gottlieb D. Long-term survival and proliferation of precursor-B acute lymphoblastic leukemia cells on human bone marrow stroma. Leukemia 1996; 10: 813–820
   PubMed Web of Science ®Google Scholar
• Bradstock K F, Gottlieb D J. Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. Leuk Lymphoma 1995; 18: 1–16
   PubMed Web of Science ®Google Scholar
• Konopleva M, Konoplev S, Hu W, et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002; 16: 1713–1724
   PubMed Web of Science ®Google Scholar
• Lagneaux L, Delforge A, De B C, Bernier M, Bron D. Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells. Leuk Lymphoma 1999; 35: 445–453
   PubMed Web of Science ®Google Scholar
• Weber M C, Tykocinski M L. Bone marrow stromal cell blockade of human leukemic cell differentiation. Blood 1994; 83: 2221–2229
   PubMed Web of Science ®Google Scholar
• Kumagai M, Manabe A, Pui C H, et al. Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest 1996; 97: 755–760
   PubMedGoogle Scholar
• Kasper B, Fruehauf S, Schiedlmeier B, et al. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors. Cancer Chemother Pharmacol 1999; 44: 433–438
   PubMed Web of Science ®Google Scholar
• Cornelissen J J, Wognum A W, Ploemacher R E, et al. Efficient long-term maintenance of chronic myeloid leukemic cobblestone area forming cells on a murine stromal cell line. Leukemia 1997; 11: 126–133
   PubMed Web of Science ®Google Scholar
• Verfaillie C M. Adhesion receptors as regulators of the hematopoietic process. Blood 1998; 92: 2609–2612
   PubMed Web of Science ®Google Scholar
• Paraguassu-Braga F H, Borojevic R, Bouzas L F, Barcinski M A, Bonomo A. Bone marrow stroma inhibits proliferation and apoptosis in leukemic cells through gap junction-mediated cell communication. Cell Death Differ 2003; 10: 1101–1108
   PubMed Web of Science ®Google Scholar
• Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999; 94: 2056–2064
   PubMed Web of Science ®Google Scholar
• Graham S M, Jorgensen H G, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319–325
   PubMed Web of Science ®Google Scholar
• Topaly J, Zeller W J, Fruehauf S. Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. Br J Haematol 2002; 119: 3–14
   PubMed Web of Science ®Google Scholar
• Lataillade J J, Clay D, Bourin P, et al. Stromal cell-derived factor 1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G(0)/G(1) transition in CD34(+) cells: evidence for an autocrine/paracrine mechanism. Blood 2002; 99: 1117–1129
   PubMed Web of Science ®Google Scholar
• Lee Y, Gotoh A, Kwon H J, et al. Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF-1/CXCL12 in synergy with other cytokines. Blood 2002; 99: 4307–4317
   PubMed Web of Science ®Google Scholar
• Spoo A C, Lubbert M, Wierda W G, Burger J A. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007; 109: 786–791
   PubMed Web of Science ®Google Scholar
• Salgia R, Quackenbush E, Lin J, et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1α. Blood 1999; 94: 4233–4246
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Srbic K, Seggewiss R, Topaly J, Ho A D. Functional characterization of podia formation in normal and malignant hematopoietic cells. J Leukoc Biol 2002; 71: 425–432
   PubMed Web of Science ®Google Scholar
• Peled A, Hardan I, Trakhtenbrot L, et al. Immature leukemic CD34 + CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1. Stem Cells 2002; 20: 259–266
   PubMed Web of Science ®Google Scholar
• Broxmeyer H E, Orschell C M, Clapp D W, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307–1318
   PubMed Web of Science ®Google Scholar
• Devine S M, Flomenberg N, Vesole D H, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin lymphoma. J Clin Oncol 2004; 22: 1095–1102
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Ehninger G, Hübel K, et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2009, 2009 Jul 13. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Veldwijk MR, Seeger T, et al. A combination of granulocyte colony-stimulating factor (G-CSF) and AMD3100 (plerixafor) mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study with AMD3100. Cytotherapy 2009, in press
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726
   PubMed Web of Science ®Google Scholar
• Liles W C, Broxmeyer H E, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728–2730
   PubMed Web of Science ®Google Scholar
• Breems D A, Blokland E A, Neben S, Ploemacher R E. Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia 1994; 8: 1095–1104
   PubMed Web of Science ®Google Scholar
• Smith M L, Sperandio M, Galkina E V, Ley K. Autoperfused mouse flow chamber reveals synergistic neutrophil accumulation through P-selectin and E-selectin. J Leukoc Biol 2004; 76: 985–993
   PubMed Web of Science ®Google Scholar
• Lyons A B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000; 243: 147–154
   PubMed Web of Science ®Google Scholar
• Pegoraro L, Matera L, Ritz J, et al. Establishment of a Ph1-positive human cell line (BV173). J Natl Cancer Inst 1983; 70: 447–453
   PubMed Web of Science ®Google Scholar
• Papayannopoulou T, Priestley G V, Nakamoto B, et al. Synergistic mobilization of hemopoietic progenitor cells using concurrent β1 and β2 integrin blockade or β2-deficient mice. Blood 2001; 97: 1282–1288
   PubMed Web of Science ®Google Scholar
• Dercksen M W, Rodenhuis S, Dirkson M K, et al. Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. J Clin Oncol 1995; 13: 1922–1932
   PubMed Web of Science ®Google Scholar
• Fruehauf S, Topaly J, Schad M, et al. Imatinib restores expression of CD62L in BCR-ABL-positive cells. J Leukoc Biol 2003; 73: 600–603
   PubMed Web of Science ®Google Scholar
• Kikuta T, Shimazaki C, Ashihara E, et al. Mobilization of hematopoietic primitive and committed progenitor cells into blood in mice by anti-vascular adhesion molecule-1 antibody alone or in combination with granulocyte colony-stimulating factor. Exp Hematol 2000; 28: 311–317
   PubMed Web of Science ®Google Scholar
• Ley K, Tedder T F. Leukocyte interactions with vascular endothelium. New insights into selectin-mediated attachment and rolling. J Immunol 1995; 155: 525–528
   PubMed Web of Science ®Google Scholar
• DiVietro J A, Brown D C, Sklar L A, Larson R S, Lawrence M B. Immobilized stromal cell-derived factor-1α triggers rapid VLA-4 affinity increases to stabilize lymphocyte tethers on VCAM-1 and subsequently initiate firm adhesion. J Immunol 2007; 178: 3903–3911
   PubMed Web of Science ®Google Scholar
• Peled A, Grabovsky V, Habler L, et al. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. J Clin Invest 1999; 104: 1199–1211
   PubMed Web of Science ®Google Scholar
• Krämer A, Horner S, Willer A, et al. Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells. Proc Natl Acad Sci USA 1999; 96: 2087–2092
   PubMed Web of Science ®Google Scholar
• Verfaillie C M, McCarthy J B, McGlave P B. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 1992; 90: 1232–1241
   PubMed Web of Science ®Google Scholar
• Salesse S, Verfaillie C M. Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR/ABL-induced defects in integrin function in CML. Oncogene 2002; 21: 8605–8611
   PubMed Web of Science ®Google Scholar
• Agis H, Jaeger E, Doninger B, et al. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. Eur J Clin Invest 2006; 36: 402–408
   PubMed Web of Science ®Google Scholar
• Juarez J, Bradstock K F, Gottlieb D J, Bendall L J. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003; 17: 1294–1300
   PubMed Web of Science ®Google Scholar
• Geay J F, Buet D, Zhang Y, et al. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 2005; 65: 2676–2683
   PubMed Web of Science ®Google Scholar
• Jin L, Tabe Y, Konoplev S, et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 2008; 7: 48–58
   PubMed Web of Science ®Google Scholar
• Möhle R, Bautz F, Rafii S, et al. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 1998; 91: 4523–4530
   PubMed Web of Science ®Google Scholar